by Nick Hudson
LONDON, Mar 21 (APM) - HIV specialist ViiV Healthcare is rated highest by patients, with AbbVie in second place, while Hospira was rated lowest of 47 pharma companies, just below Valeant, it was announced on Tuesday.
"ViiV Healthcare has made the remarkable achievement of being ranked not only first overall in 2016, but also first for all seven indicators of corporate reputation," said the report called 'Corporate Reputation of Pharma in 2016 - The Patient Perspective', which is based on the feedback of patient groups and compiled by UK-based research, publishing and consultancy group PatientView.
ViiV Healthcare was established in 2009 by GlaxoSmithKline and Pfizer and joined in 2012 by Shionogi (with stakes of 78%, 12% and 10% respectively).
AbbVie is ranked second overall and is also second for six of the seven indicators of corporate reputation (the exception was high-quality products, for which it ranked third). The survey was carried out between November 2016 and early February 2017, based on feedback from 1,463 patient groups in 105 countries.
The seven indicators of corporate reputation the 47 companies were assessed on were patient centricity, patient information, patient safety, useful products, transparency, integrity and effectiveness of patient-group relationships.
New to the overall top tier is Grifols, up from 25th in 2015 to overall sixth in 2016. Shire is up from 21st in 2015 to overall 10th in 2016. "The radical jump for both companies was due to positive feedback for them from haemophilia patient groups, which responded in greater numbers in 2016."
Pfizer slipped out of the top tier, dropping one place to overall 12th in 2016. However, it ranks in the top tier for four of the seven indicators of corporate reputation, it said.
Responses in 2016 from haemophilia patient groups also increased the rankings of Octapharma (up from 42nd in 2015 to overall 24th in 2016).
Allergan's jump in the rankings, from 39th in 2015 to overall 26th in 2016, was primarily due to favourable feedback from patient groups in Scandinavia and South Asia/South-East Asia, as well as from the 35 respondent neurological patient groups worldwide that were familiar with the company, the report said.
Amgen, which jumped from 26th in 2015 to overall 19th in 2016, gained positive feedback from the 107 respondent cancer patient groups familiar with the company. Chiesi moved up from 36th in 2015 to overall 30th in 2016, primarily due to positive feedback from rare disease patient groups.
GlaxoSmithKline jumped from 17th in 2015 to overall 13th in 2016, due to positive feedback from 36 patient groups from South Asia/South-East Asia, and 39 respiratory/allergy patient groups worldwide, it said.
The report said 63% of the 1,463 respondent patient groups claimed familiarity with Pfizer - making the company the most well-known worldwide among patient groups.
Next came Novartis (60%), Roche (54%), Bayer (51%), and Merck & Co (42%). These five companies rank both high and low for corporate reputation in 2016. "Thus, the results show that little correlation exists (at least among the larger multinationals) between familiarity and corporate reputation, as perceived by patient groups," it added.
Respondent patient groups were also asked to state which companies they had worked with in the past five years. In 2016, Novartis is ranked top, with 395 patient groups stating that they had worked with the company within the past five years.
Following up were Pfizer (329), Roche (316), AbbVie (247), Janssen (242), and Bayer (206).
The patient groups put forward a number of recommendations to improve 'patient centricity' including, increased partnering with patient groups, listening more to patients, considering drugs' costs, increased participation in clinical trials and tailoring services to individual patients.
Highest ranked
- Viiv Healthcare
- AbbVie
- Novartis
- Novo Nordisk
- Gilead Sciences
- Grifols
- Janssen
- Roche
- Lundbeck
- Shire
Lowest ranked
- 38. Menarini
- 39. Ferring
- 40. Merck KGaA
- 41. Admiral
- 42. Servier
- 43. Sandoz
- 44. Bial
- 45. Stada
- 46. Valeant
- 47. Hospira
/nh/clg
TRY APM Market Access AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to the latest stories
Our coverage includes:
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
REQUEST
an initial 10 day temporary access of APM Market Access.
